CA2281708C - Process for preparing eprosartan - Google Patents

Process for preparing eprosartan Download PDF

Info

Publication number
CA2281708C
CA2281708C CA002281708A CA2281708A CA2281708C CA 2281708 C CA2281708 C CA 2281708C CA 002281708 A CA002281708 A CA 002281708A CA 2281708 A CA2281708 A CA 2281708A CA 2281708 C CA2281708 C CA 2281708C
Authority
CA
Canada
Prior art keywords
compound
acid
imidazol
butyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002281708A
Other languages
English (en)
French (fr)
Other versions
CA2281708A1 (en
Inventor
Joseph Robert Flisak
Li Liu
Clifford S. Labaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CA2281708A1 publication Critical patent/CA2281708A1/en
Application granted granted Critical
Publication of CA2281708C publication Critical patent/CA2281708C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
CA002281708A 1997-02-14 1998-02-13 Process for preparing eprosartan Expired - Fee Related CA2281708C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3819597P 1997-02-14 1997-02-14
US60/038,195 1997-02-14
PCT/US1998/002412 WO1998035963A1 (en) 1997-02-14 1998-02-13 Process for preparing eprosartan

Publications (2)

Publication Number Publication Date
CA2281708A1 CA2281708A1 (en) 1998-08-20
CA2281708C true CA2281708C (en) 2007-08-14

Family

ID=21898583

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002281708A Expired - Fee Related CA2281708C (en) 1997-02-14 1998-02-13 Process for preparing eprosartan

Country Status (41)

Country Link
US (1) US6172237B1 (US06559137-20030506-C00112.png)
EP (1) EP0970073B1 (US06559137-20030506-C00112.png)
JP (1) JP4537499B2 (US06559137-20030506-C00112.png)
KR (1) KR100573638B1 (US06559137-20030506-C00112.png)
CN (1) CN1085208C (US06559137-20030506-C00112.png)
AP (1) AP1128A (US06559137-20030506-C00112.png)
AR (1) AR011125A1 (US06559137-20030506-C00112.png)
AT (1) ATE280765T1 (US06559137-20030506-C00112.png)
AU (1) AU730383B2 (US06559137-20030506-C00112.png)
BG (1) BG63804B1 (US06559137-20030506-C00112.png)
BR (1) BR9808664A (US06559137-20030506-C00112.png)
CA (1) CA2281708C (US06559137-20030506-C00112.png)
CO (1) CO4950550A1 (US06559137-20030506-C00112.png)
CY (1) CY2555B1 (US06559137-20030506-C00112.png)
CZ (1) CZ296349B6 (US06559137-20030506-C00112.png)
DE (1) DE69827240T2 (US06559137-20030506-C00112.png)
DK (1) DK0970073T3 (US06559137-20030506-C00112.png)
EA (1) EA001659B1 (US06559137-20030506-C00112.png)
EG (1) EG23935A (US06559137-20030506-C00112.png)
ES (1) ES2231963T3 (US06559137-20030506-C00112.png)
HU (1) HU228781B1 (US06559137-20030506-C00112.png)
ID (1) ID23181A (US06559137-20030506-C00112.png)
IL (1) IL131309A (US06559137-20030506-C00112.png)
IN (2) IN187999B (US06559137-20030506-C00112.png)
MA (1) MA24470A1 (US06559137-20030506-C00112.png)
MY (1) MY118704A (US06559137-20030506-C00112.png)
NO (1) NO317194B1 (US06559137-20030506-C00112.png)
NZ (1) NZ337180A (US06559137-20030506-C00112.png)
OA (1) OA11146A (US06559137-20030506-C00112.png)
PE (1) PE59299A1 (US06559137-20030506-C00112.png)
PL (1) PL192838B1 (US06559137-20030506-C00112.png)
PT (1) PT970073E (US06559137-20030506-C00112.png)
RO (1) RO119719B1 (US06559137-20030506-C00112.png)
SA (1) SA98190082B1 (US06559137-20030506-C00112.png)
SI (1) SI0970073T1 (US06559137-20030506-C00112.png)
SK (1) SK285036B6 (US06559137-20030506-C00112.png)
TR (1) TR199901936T2 (US06559137-20030506-C00112.png)
TW (1) TW399050B (US06559137-20030506-C00112.png)
UA (1) UA54487C2 (US06559137-20030506-C00112.png)
WO (1) WO1998035963A1 (US06559137-20030506-C00112.png)
ZA (1) ZA981207B (US06559137-20030506-C00112.png)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008078330A1 (en) * 2006-12-27 2008-07-03 Hetero Drugs Limited Improved process for eprosartan
EP2181109A4 (en) * 2007-07-25 2011-08-03 Hetero Drugs Ltd CRYSTALLINE PARTICLES OF EPROSARTAN MESYLATE AND PROCESS FOR PREPARING PURE EPROSARTAN
EP2295430A3 (en) * 2007-07-25 2011-08-03 Hetero Drugs Limited Crystalline solid of eprosartan acetate
WO2009084028A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd Improved process for manufacturing anhydrous (e)-3-[2-butyl-1- {(4-carboxyphenyl) methyl}-1h-imidazole-5-yl]-(thiophen-2- ylmethyl)prop-2-enoic acid methane sulfonate
CN101215284B (zh) * 2007-12-31 2010-10-13 浙江华海药业股份有限公司 一种改进的依普罗沙坦的制备方法
WO2009122421A2 (en) * 2008-03-31 2009-10-08 Hetero Research Foundation Improved process for eprosartan intermediate
WO2010023688A2 (en) * 2008-08-25 2010-03-04 Matrix Laboratories Limited An improved process for the preparation of eprosartan
WO2011004384A2 (en) 2009-06-05 2011-01-13 Glochem Industries Limited Process for the preparation of eprosartan
WO2011051975A1 (en) 2009-10-30 2011-05-05 Matrix Laboratories Ltd An improved process for the preparation of pure eprosartanand its pharmaceutical acceptable salts

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
NZ239161A (en) * 1990-07-31 1994-01-26 Smithkline Beecham Corp Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments,
EP0563238B1 (en) * 1990-12-14 2002-05-22 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
US5395847A (en) * 1993-12-02 1995-03-07 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
PL185858B1 (pl) * 1994-05-20 2003-08-29 Smithkline Beecham Corp Związek addycyjny kwasu 4-[(2-n-butylo-5-formylo-1Związek addycyjny kwasu 4-[(2-n-butylo-5-formylo-1H-imidazol-1-ilo)metylo]benzoesowego z wodorosiarcH-imidazol-1-ilo)metylo]benzoesowego z wodorosiarczynem i sposób jego wytwarzaniazynem i sposób jego wytwarzania

Also Published As

Publication number Publication date
EA001659B1 (ru) 2001-06-25
AU730383B2 (en) 2001-03-08
KR20000071007A (ko) 2000-11-25
HU228781B1 (en) 2013-05-28
RO119719B1 (ro) 2005-02-28
BR9808664A (pt) 2000-07-11
BG103650A (en) 2000-06-30
IN187999B (US06559137-20030506-C00112.png) 2002-08-03
EG23935A (en) 2008-01-14
CY2555B1 (en) 2008-07-02
US6172237B1 (en) 2001-01-09
NO317194B1 (no) 2004-09-13
PT970073E (pt) 2005-02-28
HUP0001994A3 (en) 2001-07-30
IN192743B (US06559137-20030506-C00112.png) 2004-05-15
PE59299A1 (es) 1999-09-09
IL131309A (en) 2002-09-12
SI0970073T1 (en) 2005-02-28
AP9901620A0 (en) 1999-09-30
PL335075A1 (en) 2000-04-10
HUP0001994A2 (hu) 2001-06-28
SA98190082B1 (ar) 2006-08-20
MY118704A (en) 2005-01-31
ATE280765T1 (de) 2004-11-15
PL192838B1 (pl) 2006-12-29
CN1085208C (zh) 2002-05-22
EP0970073B1 (en) 2004-10-27
AR011125A1 (es) 2000-08-02
EP0970073A1 (en) 2000-01-12
KR100573638B1 (ko) 2006-04-26
SK108799A3 (en) 2000-05-16
CA2281708A1 (en) 1998-08-20
WO1998035963A1 (en) 1998-08-20
ZA981207B (en) 1998-11-12
DK0970073T3 (da) 2005-02-21
CZ285299A3 (cs) 2000-02-16
JP4537499B2 (ja) 2010-09-01
NO993913L (no) 1999-08-13
TR199901936T2 (xx) 2000-04-21
EP0970073A4 (en) 2001-01-24
MA24470A1 (fr) 1998-10-01
NO993913D0 (no) 1999-08-13
BG63804B1 (bg) 2003-01-31
SK285036B6 (sk) 2006-05-04
AP1128A (en) 2002-12-06
OA11146A (en) 2003-04-16
CZ296349B6 (cs) 2006-02-15
ID23181A (id) 2000-03-23
NZ337180A (en) 2000-11-24
DE69827240D1 (de) 2004-12-02
EA199900740A1 (ru) 2000-02-28
TW399050B (en) 2000-07-21
CN1247539A (zh) 2000-03-15
ES2231963T3 (es) 2005-05-16
IL131309A0 (en) 2001-01-28
UA54487C2 (uk) 2003-03-17
AU6150898A (en) 1998-09-08
JP2001510466A (ja) 2001-07-31
CO4950550A1 (es) 2000-09-01
DE69827240T2 (de) 2005-10-13

Similar Documents

Publication Publication Date Title
CA2281708C (en) Process for preparing eprosartan
US6458963B1 (en) Process for preparing eprosartan using regioselective protection of 2,4-disubstituted-imidazole intermediates
MXPA99007533A (en) Process for preparing eprosartan
MXPA99007536A (en) Process for preparing eprosartan

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160215